199 related articles for article (PubMed ID: 23702662)
1. Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival.
Siragusa M; Sessa WC
Arterioscler Thromb Vasc Biol; 2013 Aug; 33(8):1852-60. PubMed ID: 23702662
[TBL] [Abstract][Full Text] [Related]
2. Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K/Akt/eNOS pathway and NO release in spontaneously hypertensive rats.
Xu L; Liu Y
Physiol Res; 2013; 62(4):351-9. PubMed ID: 23590610
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.
Wang WW; Zhang FL; Chen JH; Chen XH; Fu FY; Tang MR; Chen LL
Can J Physiol Pharmacol; 2015 Aug; 93(8):657-65. PubMed ID: 26158699
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
[TBL] [Abstract][Full Text] [Related]
5. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan.
Knorr M; Hausding M; Kröller-Schuhmacher S; Steven S; Oelze M; Heeren T; Scholz A; Gori T; Wenzel P; Schulz E; Daiber A; Münzel T
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2223-31. PubMed ID: 21757654
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K/Akt/eNOS pathway.
Li H; Lu W; Cai WW; Wang PJ; Zhang N; Yu CP; Wang DL; Liu BC; Sun W
Pulm Pharmacol Ther; 2014 Jun; 28(1):17-24. PubMed ID: 24269521
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study.
Littlejohn TW; Majul CR; Olvera R; Seeber M; Kobe M; Guthrie R; Oigman W;
Postgrad Med; 2009 Mar; 121(2):5-14. PubMed ID: 19332958
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARγ and the Akt/GSK-3β pathway.
Pang T; Sun LX; Wang T; Jiang ZZ; Liao H; Zhang LY
Acta Pharmacol Sin; 2014 Jun; 35(6):727-37. PubMed ID: 24793312
[TBL] [Abstract][Full Text] [Related]
9. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S; Morishita A; Ogawa K; Tadokoro T; Chiyo T; Kato K; Kobara H; Mori H; Iwama H; Masaki T
Oncotarget; 2017 Jan; 8(5):8536-8549. PubMed ID: 28052030
[TBL] [Abstract][Full Text] [Related]
10. Renal and vascular protective effects of telmisartan in patients with essential hypertension.
Morimoto S; Yano Y; Maki K; Sawada K
Hypertens Res; 2006 Aug; 29(8):567-72. PubMed ID: 17137211
[TBL] [Abstract][Full Text] [Related]
11. Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.
Mason RP; Jacob RF; Kubant R; Jacoby A; Louka F; Corbalan JJ; Malinski T
Br J Clin Pharmacol; 2012 Jul; 74(1):141-6. PubMed ID: 22283728
[TBL] [Abstract][Full Text] [Related]
12. Review: a single-pill combination of telmisartan plus amlodipine for the treatment of hypertension.
Guthrie RM
Postgrad Med; 2011 Nov; 123(6):58-65. PubMed ID: 22104454
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension.
Marketou ME; Kontaraki JE; Tsakountakis NA; Zacharis EA; Kochiadakis GE; Arfanakis DA; Parthenakis F; Chlouverakis G; Vardas PE
Am J Cardiol; 2011 Jan; 107(1):59-63. PubMed ID: 21146687
[TBL] [Abstract][Full Text] [Related]
14. Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.
Fujita H; Fujishima H; Morii T; Sakamoto T; Komatsu K; Hosoba M; Narita T; Takahashi K; Takahashi T; Yamada Y
Hypertens Res; 2012 Feb; 35(2):213-20. PubMed ID: 22072110
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells.
Cianchetti S; Del Fiorentino A; Colognato R; Di Stefano R; Franzoni F; Pedrinelli R
Atherosclerosis; 2008 May; 198(1):22-8. PubMed ID: 17950296
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers.
Noh YH; Lim HS; Kim MJ; Kim YH; Choi HY; Sung HR; Jin SJ; Lim J; Bae KS
Clin Ther; 2012 Jul; 34(7):1625-35. PubMed ID: 22721873
[TBL] [Abstract][Full Text] [Related]
17. Single-pill telmisartan and amlodipine: a rational combination for the treatment of hypertension.
Suárez C
Drugs; 2011 Dec; 71(17):2295-305. PubMed ID: 22085386
[TBL] [Abstract][Full Text] [Related]
18. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
[TBL] [Abstract][Full Text] [Related]
19. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
Bekki H; Yamamoto K; Sone M; Homma T; Nakata M; Nohara M; Fukami K; Okuda S; Yamagishi S
Clin Cardiol; 2011 Apr; 34(4):261-5. PubMed ID: 21432858
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monotherapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study.
Ihm SH; Jeon HK; Cha TJ; Hong TJ; Kim SH; Lee NH; Yoon JH; Yoon N; Hwang KK; Jo SH; Youn HJ
Drug Des Devel Ther; 2016; 10():3817-3826. PubMed ID: 27920497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
